Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Zyprexa IM "Approvable"; GMP Consultants Hired In Wake Of Inspections

Executive Summary

Lilly believes Zyprexa IM is on track for a late summer launch following receipt of an "approvable" letter from FDA.
Advertisement

Related Content

FDA Approves Zyprexa IM; Milestone In Lilly GMP Turnaround
Lilly Symbyax Combo Clears FDA; Price, Dose Will Help Distinguish Brand
Lilly Forteo Labeling Talks Last Step Before Approval; GMP Issues Resolved
Lilly GMP Strategy: Avoid Consent Degree With Open Communication At FDA
Pfizer Near Resolution Of GMP Warning Letter; Lilly, Merck Provide Updates
Lilly, FDA Discussing Insulin GMP Upgrades To Avoid Supply Restrictions
Lilly Forteo "Approvable": Indications, Manufacturing Issues To Be Resolved
Lilly Consultants To Pre-Inspect Zovant Contract Manufacturing Sites
Zyprexa IM Manufacturing Issues To Be Discussed By FDA, Lilly March 15
Zyprexa IM Manufacturing Issues To Be Discussed By FDA, Lilly March 15
Advertisement
UsernamePublicRestriction

Register

PS037664

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel